Biocon has kicked off FY26 with confidence and is building momentum, setting the tone for a robust year ahead. Powered by strong gains in Biosimilars, steady growth in CRDMO, and a resilient performance in Generics, the quarter reflects more than just numbers, it's a testament to the company's ability to adapt to change and seize … Continue reading Biocon Q1FY26 Earnings is well-positioned for contined momentum and sustained growth
Biocon Biologics off to a solid start in Q1 FY25, powered byproduct sales & market shares
The successful integration of the acquired Biosimilars business dominated the Biocon Biologics growth story last year. In fiscal year 2024-25 (FY25), we have turned our focus to consolidating the acquired business and paving the way for future growth. Our performance in the first quarter of FY25 gives us confidence that we are on the right … Continue reading Biocon Biologics off to a solid start in Q1 FY25, powered byproduct sales & market shares
Biocon Reports a Robust Business Performance in FY23
The World Health Organization recently declared that Covid-19 is no longer a global health emergency. While the pandemic threat has waned, there continues to be huge unmet need for affordable essential medicines to treat chronic diseases that kill 41 million people each year. Over the last two decades, Biocon has been at the forefront of … Continue reading Biocon Reports a Robust Business Performance in FY23
A Blog by Biocon 